%0 Meta-Analysis
%T Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis.
%A Luan CW
%A Kuo LT
%A Wang YT
%A Liao CT
%A Kang CJ
%A Lee YC
%A Chen KY
%A Lai CH
%A Tsai YH
%A Huang EI
%A Tsai MS
%A Hsu CM
%A Chang GH
%A Tsai YT
%J Head Neck
%V 45
%N 7
%D 2023 07 10
%M 37161915
%F 3.821
%R 10.1002/hed.27397
%X Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69-3.38), overall survival (HR = 2.40, 95% CI 1.94-2.98), disease-specific survival (HR = 2.57, 95% CI 1.71-3.88), and disease-free survival (HR = 2.67, 95% CI 1.51-4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.